Glycosaminoglycans are polysaccharides of the extracellular matrix supporting skin wound closure. Mesoglycan is a mixture of glycosaminoglycans such as chondroitin-, dermatan-, heparan-sulfate and heparin and is the main component of PrismaÂ® Skin, a pharmaceutical device developed by Mediolanum Farmaceutici S.p.a. Here, we show the in vitro effects of this device in the new vessels formation by endothelial cells, since angiogenesis represents a key moment in wound healing. We found a strong increase of migration and invasion rates of these cells treated with mesoglycan and PrismaÂ® Skin which mediate the activation of the pathway triggered by CD44 receptor. Furthermore, endothelial cells form longer capillary-like structures with a great number of branches, in the presence of the same treatments. Thus, the device, thanks to the mesoglycan, leads the cells to the Endothelial-to-Mesenchymal Transition, suggesting the switch to a fibroblast-like phenotype, as shown by immunofluorescence assays. Finally, we found that mesoglycan and PrismaÂ® Skin inhibit inflammatory reactions such as nitric oxide secretion and NF-ÎºB nuclear translocation in endothelial cells and Tumor Necrosis Factor-Î± production by macrophages. In conclusion, based on our data, we suggest that PrismaÂ® Skin may be able to accelerate angiogenesis in skin wound healing, and regulate inflammation avoiding chronic, thus pathological, responses.
|Titolo:||The pharmaceutical device prismaÂ® skin promotes in vitro angiogenesis through endothelial to mesenchymal transition during skin wound healing|
|Data di pubblicazione:||2017|
|Appare nelle tipologie:||1.1 Articoli su Rivista|